Supporting this view, we studied a specific FGFR4 inhibitor, BLU9931, which was well tested in selected HCC cell lines and HCC xenograft models [23] with tumoral FGF19/FGFR4/β-klotho expression. The gene discussed is KLB; the disease is hepatocellular carcinoma.